Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour
about
Cytokines and chemokines at the crossroads of neuroinflammation, neurodegeneration, and neuropathic painImmunoengineering nerve repair.Analgesia for neuropathic pain by dorsal root ganglion transplantation of genetically engineered mesenchymal stem cells: initial results.The generation of knock-in mice expressing fluorescently tagged galanin receptors 1 and 2.Fractalkine mediates inflammatory pain through activation of satellite glial cellsLentiviral vectors for gene transfer into the spinal cord glial cells.International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Fractalkine/CX3CR1: why a single chemokine-receptor duo bears a major and unique therapeutic potential.Chemokines, neuronal-glial interactions, and central processing of neuropathic pain.Chemokines in neuron-glial cell interaction and pathogenesis of neuropathic pain.Bilateral elevation of interleukin-6 protein and mRNA in both lumbar and cervical dorsal root ganglia following unilateral chronic compression injury of the sciatic nerve.Targeted disruption of the orphan receptor Gpr151 does not alter pain-related behaviour despite a strong induction in dorsal root ganglion expression in a model of neuropathic pain.Elevated expression of fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in the dorsal root ganglia and spinal cord in experimental autoimmune encephalomyelitis: implications in multiple sclerosis-induced neuropathic pain.CX3CR1 Mediates Nicotine Withdrawal-Induced Hyperalgesia via Microglial P38 MAPK Signaling.Activation of cannabinoid receptor 2 attenuates mechanical allodynia and neuroinflammatory responses in a chronic post-ischemic pain model of complex regional pain syndrome type I in rats.
P2860
Q21284848-7C4A3F85-5BBD-4374-AC06-D4D6020446A8Q33865663-DADFDD4D-CAA7-430A-8AE2-0D90E2525083Q35091885-792D8026-793D-4AE6-BF4B-8DD3C7226EF5Q36159591-007E1EFD-BA9C-4532-AB70-439C0F9DD579Q36991021-E9BEF19A-3CE1-4EAA-81B3-DCFF20F93BF3Q37401091-B744F426-432F-4D31-93DC-2CAE7AB2B297Q37432097-5DACAAC7-A200-4D48-BDB2-6AAD5890B18FQ37670253-636C612C-6A5D-4A5E-BCC3-5830957CB98BQ37684327-DACE1FCC-A7FF-4544-AB42-F00B56B405C5Q39227824-68663FF2-7385-4087-8ADC-DA21F4385FB2Q40814739-FFAEF80C-D747-4982-8B78-CF85F56ACF8DQ42105348-5E2D9497-7BF8-40F0-AA0C-63ACCC2A54B9Q42106748-0EAB801E-1C1F-4A4B-A651-A038F144516FQ47650784-DE568E23-7C36-4FEE-9A7A-3CB6F21925A1Q51417508-AE15694D-E16D-4970-B177-B720A312D6C2
P2860
Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 12 April 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour
@en
Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour.
@nl
type
label
Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour
@en
Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour.
@nl
prefLabel
Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour
@en
Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour.
@nl
P2093
P2860
P1476
Intra-neural administration of fractalkine attenuates neuropathic pain-related behaviour
@en
P2093
David Wynick
Fiona E Holmes
Niall C H Kerr
Nighat Arnott
Penny Vanderplank
Philip G Popovich
Philip M Murphy
Toshio Imai
P2860
P304
P356
10.1111/J.1471-4159.2008.05419.X
P407
P577
2008-04-12T00:00:00Z